Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Protagenic Therapeutics, Inc.\new | ex99-1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 26, 2017
|
PROTAGENIC THERAPEUTICS, INC. |
|
(Exact name of Company as specified in its charter) |
|
Delaware |
|
000-51353 |
|
06-1390025 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
149 Fifth Avenue, Suite 500, New York, NY |
|
10010 |
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
212-994-8200 |
|
|
|
(Company’s telephone number, including area code) |
|
| (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD.
On May 26, 2017, Protagenic Therapeutics, Inc. (the “Company”) issued a letter to its stockholders reporting on the Company’s developmental progress toward filing an FDA Investigational New Drug (IND) application for its prospective investigation new drug application in 2018. The stockholder letter is furnished as Exhibit 99.1 hereto.
The information in this Form 8-K (including the Exhibit) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by referenced in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referenced in such a filing.
Item 9.01. Financial Statements and Exhibits.
|
Exhibit |
Description | |
|
99.1 |
Stockholder letter issued on May 26, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PROTAGENIC THERAPEUTICS, INC. |
| |
|
|
|
|
|
|
|
|
|
|
|
Date: May 26, 2017 |
By: |
/s/ Alexander K. Arrow |
|
|
|
Name: Alexander K. Arrow |
| |
|
|
Title: Chief Financial Officer |
| |
3